Early pseudoprogression and progression lesions in glioblastoma patients are both metabolically heterogeneous

The standard treatment in glioblastoma includes maximal safe resection followed by concomitant radiotherapy plus chemotherapy and adjuvant temozolomide. The first follow‐up study to evaluate treatment response is performed 1 month after concomitant treatment, when contrast‐enhancing regions may appe...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	NMR in biomedicine Ročník 37; číslo 4; s. e5095 - n/a
Hlavní autori:	Ungan, Gülnur, Pons‐Escoda, Albert, Ulinic, Daniel, Arús, Carles, Ortega‐Martorell, Sandra, Olier, Ivan, Vellido, Alfredo, Majós, Carles, Julià‐Sapé, Margarida
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Wiley Subscription Services, Inc 01.04.2024
Predmet:	Biomarkers Chemotherapy convex non‐negative matrix factorization Evaluation Glioblastoma Heterogeneity Lesions Metabolism MRS pseudoprogression Radiation therapy Temozolomide pseudoprogression convex non-negative matrix factorization glioblastoma MR MRS
ISSN:	0952-3480, 1099-1492, 1099-1492
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!